免疫疗法在三阴性乳腺癌中的作用扩大。
Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer.
机构信息
Peter MacCallum Cancer Centre, Melbourne, Australia.
Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
出版信息
Cancer Cell. 2020 May 11;37(5):623-624. doi: 10.1016/j.ccell.2020.04.007.
PMID:32396855
Abstract
PD-1 axis blockade, in combination with chemotherapy, improves outcomes in advanced triple-negative breast cancer that is PD-L1 positive. The phase 3 KEYNOTE-522 trial now shows that the addition of pembrolizumab to chemotherapy improves pathological complete response rates regardless of PD-L1 status and appears to improve survival.
摘要
PD-1 轴阻断联合化疗可改善 PD-L1 阳性的晚期三阴性乳腺癌的结局。目前，III 期 KEYNOTE-522 试验表明，帕博利珠单抗联合化疗可提高病理完全缓解率，且不受 PD-L1 状态影响，并可能改善生存。
Zotero 插件